Investor Relations

Investment History

  • US$ 14M invested by Private Investors from 2012 (founders and VCs)
  • US$ 5M invested by CSO and Innovation Authorities (Non dilutive Grants).
  • In 2019 Max Herzberg and Yochai Richter acquired all shares of the VC group as a Management buy out
  • From 2019 the Company is funded by them on a need to spend basis
  • Going to Public Market and GEM for further major funding (Phase 2 and 3 for previous project and present application)
  • Main Shareholders committed to complementary funding if necessary.
  • Funding application to Horizon (EEC) : first application submitted on NMSC Phase 3 for VDA1102.

Vidac Pharma Holding PLC

Dr. Max Herzberg
      20-22 Wenlock Road
      London N1 7GU
      United Kingdom
+972 (0)779300647
LEI: 875500BCH1T6XX5EUG13
ISIN: GB00BM9XQ619

Financial Statements

31 December 2021 Financial Statement

Download

Financial Calendar

Upcoming Events Date
6 month unaudited financial statements of 2022 30 September 2022
audited annual financial statements of 2022 30 June 2023

Clinical Trial Success

September 23, 2021

VIDAC PHARMA LTD ANNOUNCES WIDER SPECTRUM AUTHORIZATION OF ITS CTCL PHASE 2 CLINICAL TRIAL.

Rehovot, Israel Sept 20, 2021 Based of the satisfactory safety data of VIDAC VDA 1102 on selected patients, Vidac Pharma received authorization to widen the scope of the trial to CTCL whole spectrum of conditions. “We are very satisfied with the results of…
September 13, 2021

Vidac Pharma Ltd.: New Chemical Entities Patent Granted

Rehovot, Israel Sept 13, 2021 Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit systemic use…
April 19, 2021

Vidac Pharma Secures EUR 20m Capital Commitment From GEM

NESS-ZIONA, Israel, April 19, 2021 /PRNewswire/ -- Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative…
February 09, 2021

VIDAC PHARMA ANNOUNCES INCLUSION OF THE FIRST PATIENT IN A PLACEBO CONTROLLED PHASE II STUDY

Jerusalem, Israel, February 09 2021 – Vidac Pharma Ltd announces inclusion of the first Patient in a Placebo controlled Phase II study in early forms of Cutaneous T-Cell Lymphoma treated with its first in class drug VDA 1102 . VDA 1102 disrupt the binding of…
December 14, 2018

VIDAC PHARMA ANNOUNCES PUBLICATION OF A PEER REVIEWED ARTICLE ON VDA-1102 MECHANISM OF ACTION

Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol 138:2635-2643),…
November 04, 2018

VIDAC PHARMA TO PRESENT A POSTER AT THE SITC 2018 MEETING

Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster…
July 10, 2018

VIDAC PHARMA ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an early…
June 20, 2018

VIDAC PHARMA TO PRESENT A POSTER AT THE EACR25 2018 MEETING

Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic Immuno-Oncology” at the…
April 04, 2018

VIDAC PHARMA TO PRESENT AN IMMUNO-METABOLISM POSTER AT THE 2018 AACR ANNUAL MEETING 2018

Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will present an immono-metabolism poster at the AACR Annual Meeting 2018 in Chicago, Illinois. The poster…
January 23, 2018

VIDAC PHARMA TO PRESENT AT THE 2018 BIO CEO & INVESTOR CONFERENCE

Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and dermatology-focused biopharmaceutical company, today announced that Oren M. Becker, PhD, President and Chief Executive Officer, will present at the 2018 BIO CEO & Investor…
December 06, 2017

VIDAC PHARMA TO PRESENT AT THE 2018 4TH ANNUAL DERMATOLOGY INNOVATION FORUM

Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will participate as Company Spotlight presenter at the 4th Annual Dermatology Innovation Forum. The…
October 12, 2017

VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS

Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102 OINTMENT in Actinic Keratosis Establishes that VDA-1102 ointment is well-tolerated, non-irritating and safe Demonstrates reduction of number of actinic keratosis lesions in…
January 01, 2017

VIDAC PHARMA APPOINTS CHIEF MEDICAL AND CHIEF SCIENCE OFFICERS

Jerusalem, Israel, January 1, 2017 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced the appointment of Dr. Chaim Brickman as the company's Chief Medical Officer, and the appointment of Dr. Vered Behar as the company's…
December 12, 2016

VIDAC PHARMA PHASE 2A STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION

Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced that the ongoing Phase 2 study with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, in actinic keratosis (AK) met a…
July 29, 2016

VIDAC PHARMA ANNOUNCES THE INNITIATION OF A PHASE 2A STUDY OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has initiated a Phase 2 trial with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, to treat subjects with…
June 30, 2016

VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT

Jerusalem, Israel, June 30, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has completed a Phase 1a trial of VDA-1102 ointment, a topical ointment formulation of VDA-1102, a potent selective…
June 29, 2016

Vidac Pharma Completes $9 Million Series A Financing I Advances Phase 2 Studies with VDA-1102 In Actinic Keratosis

Jerusalem, Israel, June 29, 2016 – Vidac Pharma, a privately-held clinical stage pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer and oncodermatology disease, announced today that it has closed a $9 million a…
February 25, 2016

Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator

Jerusalem, Israel, February 25, 2016 – Vidac Pharma, a clinical stage drug development company, today announced the initiation of Phase I first-in-human studies with VDA-1102 ointment, its highly selective, proprietary VDAC/HK2 modulator for the treatment of…
December 30, 2015

Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis

Jerusalem, Israel, December 30, 2015 – Vidac Pharma, a drug discovery and development company, today announced the filing of an Investigational New Drug (IND) application with the U.S. FDA for VDA-1102 topical skin ointment, its highly selective, proprietary…
October 15, 2014

Vidac Pharma Appoints Dr. Chaim Brickman as Vice President of Clinical Affairs

Jerusalem, Israel, November 15, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Chaim M. Brickman, M.D. as its vice president of clinical affairs. Chaim will oversee all clinical development activities for the…
August 19, 2014

Vidac Pharma Appoints Dr. Paul Salama as Vice President of Chemistry, Manufacturing, and Control

Ness Ziona, Israel, August 19, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Dr. Paul Salama as its vice president of chemistry, manufacturing, and control (CMC). Dr. Salama brings to Vidac more than 20…

Disclaimer

The following information does not constitute an public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.